Heartflow (HTFL) Q2 2026 earnings review
Growth Accelerates, But Surging OpEx Widens Losses
Heartflow delivered a powerful top-line beat in Q2, with total revenue growth accelerating to 48% YoY ($64.1M). The U.S. business is firing on all cylinders (+51% YoY), driven by a highly successful ramp of the new Plaque Analysis product alongside durable FFR CT volumes. AI-driven operational efficiencies pushed non-GAAP gross margin to a record 83.3%. However, profitability remains elusive. A conscious decision to heavily invest in clinical research and sales headcount pushed operating expenses up 53% YoY, causing the net loss to widen to $15.7M. Management remains highly confident, significantly raising the FY26 revenue guidance to $246-$250M.
🐂 Bull Case
The rapid adoption of Heartflow Plaque Analysis is supercharging U.S. revenue, shifting the company from a single-product story to a high-growth AI platform.
The AI 'Autonomous Processing' initiative is working. Non-GAAP gross margin hit 83.3%, putting the company's mid-term target of 85% well within reach and demonstrating deep operational scalability.
🐻 Bear Case
While the U.S. booms, International revenue growth rapidly decelerated from 34% in Q1 to just 12% in Q2. Overseas adoption is failing to keep pace.
Despite a massive 62% jump in gross profit, GAAP net loss actually widened YoY (from $9.2M to $15.7M) because operating expenses surged 53% YoY, delaying the timeline to true profitability.
⚖️ Verdict: 🟢
Bullish. The widening net loss is a conscious investment in growth, not a structural flaw. The combination of 48% revenue growth, 83.3% gross margins, and a massive full-year guidance raise proves Heartflow's core AI flywheel is gaining unstoppable momentum.
Key Themes
Plaque Analysis Driving U.S. Acceleration
U.S. revenue growth is accelerating sharply, reaching 51% YoY in Q2 (up from 42% in Q1). Management explicitly tied this acceleration to the rising case volumes of the Heartflow Plaque Analysis product. Expanding payor coverage (now covering 75% of U.S. lives) is clearly translating directly into rapid volume scaling.
International Segment Severely Lagging
A concerning divergence emerged this quarter: while U.S. growth accelerated, International revenue growth decelerated dramatically to just 12% YoY (down from 34% in Q1 and 35% in Q4). International revenue contributed only $4.5M, suggesting Heartflow's core commercial engine and Plaque product momentum is heavily constrained to the U.S. market.
AI Autonomous Processing Pushes Margins Higher
The company's proprietary data moat (over 200 million annotated CTA images) is driving real margin leverage. The rollout of AI efficiency initiatives in the production team pushed non-GAAP gross margin up to 83.3% (from 75.6% a year ago). The business is now comfortably tracking toward its 85% mid-term target.
Aggressive OpEx Investments Widening Losses
Despite 48% top-line growth, Heartflow's GAAP net loss widened to $15.7M from $9.2M a year ago. This was driven by a reversing operating leverage trajectory: R&D expenses skyrocketed 75% YoY to $26.3M, and SG&A climbed 42% YoY to $44.8M. While management positions this as necessary investment in clinical research and sales headcounts, it contradicts the prior quarter's narrative of steadily improving operating leverage.
Structural Macro Tailwinds: The CT-First Pathway
The underlying structural shift in cardiovascular care toward a 'CT-first' diagnostic pathway provides a durable tailwind. This guideline-backed shift supports consistent base volume growth for the legacy FFR CT product, upon which the high-margin Plaque and Navigator products are being layered.
Other KPIs
Stable. Adjusted EBITDA loss narrowed slightly compared to $(10.1) million in the prior year period. However, this non-GAAP measure excludes an increasingly large stock-based compensation burden ($7.9M this quarter, up from $2.3M a year ago), which masks the true cash-equivalent burn profile of the expanding headcount.
Combined with long-term investments, total liquidity stands at $246.8 million. Given the current non-GAAP net operating loss run-rate of ~$32M annualized, the company remains highly capitalized to self-fund its R&D initiatives and reach cash-flow profitability without near-term dilution.
Guidance
Accelerating. Raised significantly from the prior $228M - $232M range. The new midpoint ($248M) implies an exceptional 40% to 42% YoY growth rate. Given that Q1 and Q2 grew at 41% and 48% respectively, this suggests management expects sustained >40% growth in the back half of the year, likely banking on further Plaque adoption.
Accelerating. Raised from the previous target of ~81%. With Q2 already printing at 83.3%, the full-year target appears somewhat conservative, but it locks in the narrative that Heartflow has permanently elevated its margin profile through AI.
Key Questions
International Deceleration Drivers
International revenue growth slowed significantly to 12% YoY. Is this due to delayed regulatory approvals for Plaque, specific reimbursement hurdles abroad, or competitive pressures?
Timeline for Operating Leverage
With R&D up 75% YoY this quarter, when does management anticipate the pace of OpEx growth to normalize, and when will top-line outperformance fully translate to a narrowing GAAP net loss?
Plaque Cannibalization vs Attach Rate
Are you seeing Plaque Analysis being ordered as a standalone diagnostic tool, or is it strictly attaching to existing FFR CT cases? How is this impacting blended ASPs?